The Orphan Nuclear Receptor SHP Inhibits Agonist-dependent Transcriptional Activity of Estrogen Receptors ERα and ERβ*

SHP (short heterodimer partner) is an unusual orphan nuclear receptor that contains a putative ligand-binding domain but lacks a conserved DNA-binding domain. Although no conventional receptor function has yet been identified, SHP has been proposed to act as a negative regulator of nuclear receptor signaling pathways, because it interacts with and inhibits DNA binding and transcriptional activity of various nonsteroid receptors, including thyroid hormone and retinoid receptors. We show here that SHP interacts directly with agonist-bound estrogen receptors, ERα and ERβ, and inhibits ER-mediated transcriptional activation. SHP specifically targets the ligand-regulated activation domain AF-2 and competes for binding of coactivators such as TIF2. Thus, SHP may represent a new category of negative coregulators for ligand-activated nuclear receptors. SHP mRNA is widely expressed in rat tissues including certain estrogen target tissues, and subcellular localization studies demonstrate that SHP is a nuclear protein, suggesting a biological significance of the SHP interactions with ERs. Taken together, these results identify ERs as novel SHP targets and suggest that competition for coactivator-binding is a novel mechanism by which SHP may inhibit nuclear receptor activation.

[1]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[2]  J. Milbrandt,et al.  Nuclear Receptor DAX-1 Recruits Nuclear Receptor Corepressor N-CoR to Steroidogenic Factor 1 , 1998, Molecular and Cellular Biology.

[3]  R. Evans,et al.  The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. , 1997, Genes & development.

[4]  S. Cowley,et al.  Estrogen Receptors α and β Form Heterodimers on DNA* , 1997, The Journal of Biological Chemistry.

[5]  M. Lazar,et al.  Stoichiometric and steric principles governing repression by nuclear hormone receptors. , 1997, Genes & development.

[6]  B. O’Malley,et al.  Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. , 1998, Science.

[7]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[8]  J. T. Kadonaga,et al.  p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. , 1998, Genes & development.

[9]  M. Rao,et al.  Cloning and Identification of Rat Deoxyuridine Triphosphatase as an Inhibitor of Peroxisome Proliferator-activated Receptor α* , 1996, The Journal of Biological Chemistry.

[10]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[11]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[12]  H. Gronemeyer,et al.  The coactivator TIF2 contains three nuclear receptor‐binding motifs and mediates transactivation through CBP binding‐dependent and ‐independent pathways , 1998, The EMBO journal.

[13]  D. Moore,et al.  An Orphan Nuclear Hormone Receptor That Lacks a DNA Binding Domain and Heterodimerizes with Other Receptors , 1996, Science.

[14]  C. Glass,et al.  Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding , 1994, Nature.

[15]  J. Gustafsson,et al.  Heterodimeric interaction between retinoid X receptor alpha and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation , 1997, Molecular and cellular biology.

[16]  M. Haussler,et al.  Heterodimeric DNA Binding by the Vitamin D Receptor and Retinoid X Receptors Is Enhanced by 1,25-Dihydroxyvitamin D3 and Inhibited by 9-cis-Retinoic Acid , 1998, The Journal of Biological Chemistry.

[17]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[18]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[19]  D. Moore,et al.  Novel receptor interaction and repression domains in the orphan receptor SHP , 1997, Molecular and cellular biology.

[20]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[21]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[22]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[23]  P B Sigler,et al.  Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  E. Kalkhoven,et al.  Ligand‐independent activation of the oestrogen receptor by mutation of a conserved tyrosine , 1997, The EMBO journal.

[25]  C. Allis,et al.  Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.

[26]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[27]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[28]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[29]  M. Ito,et al.  DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita , 1997, Molecular and cellular biology.

[30]  G. Hammer,et al.  Wilms' Tumor 1 and Dax-1 Modulate the Orphan Nuclear Receptor SF-1 in Sex-Specific Gene Expression , 1998, Cell.

[31]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[32]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[33]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[34]  N. Koibuchi,et al.  TRAM-1, A Novel 160-kDa Thyroid Hormone Receptor Activator Molecule, Exhibits Distinct Properties from Steroid Receptor Coactivator-1* , 1997, The Journal of Biological Chemistry.

[35]  D. Moore,et al.  Structure and Expression of the Orphan Nuclear ReceptorSHP Gene* , 1998, The Journal of Biological Chemistry.

[36]  V. Chatterjee,et al.  Thyroid Hormone-mediated Enhancement of Heterodimer Formation between Thyroid Hormone Receptor β and Retinoid X Receptor* , 1997, The Journal of Biological Chemistry.

[37]  K. Umesono,et al.  Unique response pathways are established by allosteric interactions among nuclear hormone receptors , 1995, Cell.

[38]  E. Lalli,et al.  DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis , 1997, Nature.

[39]  B. O’Malley,et al.  A thyroid hormone receptor coactivator negatively regulated by the retinoblastoma protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[41]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[43]  D. Moore,et al.  Interaction of thyroid-hormone receptor with a conserved transcriptional mediator , 1995, Nature.

[44]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[45]  M. Stallcup,et al.  Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology* , 1998, The Journal of Biological Chemistry.

[46]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[47]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[48]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Tsukamoto,et al.  An orphan nuclear receptor lacking a zinc-finger DNA-binding domain: interaction with several nuclear receptors. , 1997, Biochimica et biophysica acta.

[51]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[52]  J. Gustafsson,et al.  Cloning and Expression of a Novel Mammalian Thioredoxin* , 1997, The Journal of Biological Chemistry.